IGF2BP3 and acute myeloid leukemia: Furthermore, the CRISPR/Cas9-mediated IGF2BP3 knockout makes AML cells more sensitive to serine and glycine (SG) deprivation, and ultimately demonstrates that IGF2BP3 silencing combined with dietary SG restriction effectively inhibits AML (164).